Cutler Group LP Aeterna Zentaris Inc. Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 26, 2021	SELL	$0.59 - $0.88 $7,608 - $11,347	-12,895 Reduced 46.31%	14,949 $11,000
Q2 2021 Jul 19, 2021	BUY	$0.83 - $1.14 $20,205 - $27,752	24,344 Added 695.54%	27,844 $24,000
Q2 2019 Aug 09, 2019	BUY	$2.04 - $5.43 $816 - $2,172	400 Added 12.9%	3,500 $10,000
Q1 2019 May 10, 2019	BUY	$3.03 - $4.65 $9,090 - $13,950	3,000 Added 3000.0%	3,100 $14,000
Q4 2018 Feb 05, 2019	BUY	$1.3 - $3.87 $130 - $387	100 New	100 $0
Q3 2018 Nov 07, 2018	SELL	$1.6 - $2.03 $1,440 - $1,826	-900 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$1.46 - $2.41 $584 - $964	400 Added 80.0%	900 $1,000
Q4 2017 Jan 17, 2018	SELL	$1.87 - $2.7 $3,179 - $4,590	-1,700 Reduced 77.27%	500 $1,000
Q3 2017 Oct 17, 2017	BUY	$1.81 - $2.23 $3,982 - $4,906	2,200	2,200 $4,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.